Natera
Natera is a publicly traded cell-free DNA testing company that provides MRD oncology (Signatera), transplant rejection (Prospera), and reproductive health (Panorama) tests to clinicians, health systems, and biopharma partners, processing over 16 million cumulative tests across its CAP/CLIA-certified laboratories.
- Company typePublic
- Founded2004
- HeadquartersSan Carlos, United States
- Headcount5,001–10,000
- GTM typeB2B
- OfferingServices
What Natera does
Natera, Inc. is a publicly traded (NASDAQ: NTRA) cell-free DNA (cfDNA) testing company founded in 2004 and headquartered in Austin, Texas, with operations in San Carlos, California and (via the Foresight Diagnostics acquisition) Boulder, Colorado. The company operates proprietary molecular and bioinformatics platforms built on multiplexed PCR and next-generation sequencing to detect and quantify circulating tumor DNA, donor-derived cfDNA, fetal cfDNA, and germline variants from a single blood draw. Flagship products include Signatera (tumor-informed, bespoke ctDNA minimal residual disease / MRD assay), Prospera (donor-derived cfDNA with the proprietary Donor Quantity Score algorithm for transplant rejection), Panorama (SNP-based non-invasive prenatal testing), Empower (hereditary cancer screening), Vistara (single-gene NIPT), and Zenith (whole-genome sequencing for rare disease). Natera runs ISO 13485, CAP, and CLIA-certified labs, holds SOC 2 Type II compliance, and is FDA-cleared for the Signatera CDx in muscle-invasive bladder cancer as of May 2026.
Natera generates revenue through clinical testing services billed to payors and health systems (with oncology ASP around $1,250 per Signatera test in Q1 2026), a dedicated BioPharma services unit that licenses Signatera MRD endpoints and provides real-world data access to trial sponsors, and licensing royalties following the April 2026 court award of a 30% royalty on infringing MRD products. Customers span five distinct segments: oncologists and cancer centers (over half of U.S. oncologists use Signatera), women's health providers (OB/GYNs and maternal-fetal medicine specialists), transplant centers, biopharma sponsors (including Allogene, Genentech, Diakonos, CytoDyn, and Purespring), and rare-disease patients via the Zenith platform. The go-to-market motion is direct enterprise field sales to clinicians and health systems, supplemented by channel partnerships (SRL Inc. in Japan, Pirche AG in transplant) and heavy clinical evidence generation that drives guideline inclusion.
The company has processed over 16 million cumulative tests, maintains a proprietary oncology database with 2M+ plasma timepoints, and reports approximately 50% market share in tumor-informed MRD testing. Investment in scientific marketing — 35 abstracts at ASCO 2026, 20 at AACR 2026, 21 at ATC 2026, and 400+ peer-reviewed publications — supports three NCCN guideline recommendations, including Category 1 for Signatera. Q1 2026 revenue of $696.6M (+38.8% YoY) implies TTM revenue of approximately $2.5B and FY2026 revenue in the $2.8B range, with gross margins near 65% and a market capitalization of approximately $30–31B. The announced Austin headquarters expansion (May 2026) will add roughly 400 new roles alongside the company's largest sequencing facility.
Natera firmographics
Firmographics- Name
- Natera
- Legal name
- Natera, Inc.
- Website
- https://natera.com
- Company type
- Public
- Founded year
- 2004
- Operating status
- Operating
- Headcount range
- 5,001–10,000 employees
- Short description
- Natera is a publicly traded cell-free DNA testing company that provides MRD oncology (Signatera), transplant rejection (Prospera), and reproductive health (Panorama) tests to clinicians, health systems, and biopharma partners, processing over 16 million cumulative tests across its CAP/CLIA-certified laboratories.
- Ownership category
- akta.pro rank
Where Natera is headquartered
LocationHeadquarters
- HQ city
- San Carlos
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
Natera business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Clinical diagnostic testing services: Revenue from running cell-free DNA tests (Signatera, Latitude, Altera, Empower, Prospera, Renasight, Panorama, Horizon, Vistara, Anora, Fetal Focus, Zenith) in CAP/CLIA-certified labs for clinicians, hospitals, health systems, and patients. ASPs in oncology testing were approximately $1,250 in Q1 2026, with 54-55% YoY oncology test volume growth.
- Biopharma services and partnerships: Revenue from biopharma customers using Signatera, CLARITY, and RenasightIQ for clinical trial MRD testing, molecular response analysis, real-world data access, and companion-diagnostic development (e.g., Diakonos, CytoDyn, Allogene, Genentech, Diakonos, Purespring/Travere collaborations).
- MRD patent licensing royalties: Licensing royalties on MRD-related patents; a U.S. court awarded Natera a 30% ongoing royalty on revenues from infringing MRD-related products (including ArcherDx and Invitae product sales), establishing a recurring royalty revenue stream.
- Renasight / RenasightIQ pharma research and clinical-trial services: Revenue from genetic testing panels (Renasight kidney gene panel) and pharma research services that accelerate rare-disease and chronic kidney disease clinical trial recruitment (e.g., Alport, ADPKD, FSGS case studies).
Go-to-market motion4 records
Distribution channels5 records
Marketing channels7 records
Natera product offering
Product offeringCore offering
Natera runs cell-free DNA (cfDNA) diagnostic tests in its ISO 13485/CAP/CLIA-certified laboratories, sold to clinicians, health systems, and biopharma customers. Its core franchise is Signatera, a personalized tumor-informed molecular residual disease (MRD) assay for cancer recurrence monitoring, complemented by Prospera dd-cfDNA transplant rejection tests (kidney, heart, lung), Panorama NIPT and women's health reproductive tests, Renasight kidney gene panels, and the Zenith whole-genome rare-disease platform.
Product overview
Natera operates a platform-plus-modules architecture centered on its NateraCore laboratory services infrastructure and NateraConnect provider portal, with the test menu organized into four clinical franchises: (1) Oncology — anchored by Signatera (tumor-informed MRD) and Signatera Genome, complemented by Latitude (tissue-free MRD), Altera (tumor genomic profiling), Spectrum, Empower (hereditary cancer), and the acquired CLARITY MRD assay from Foresight Diagnostics; (2) Transplant — Prospera dd-cfDNA assessment for kidney, heart, and lung recipients; (3) Kidney genetics — Renasight and RenasightIQ panels; and (4) Reproductive health — Panorama NIPT, Vistara, Fetal Focus, Vasistera, Anora, and Horizon carrier screening. Beyond the clinical test menu, the Zenith whole-genome rare-disease platform, Annotation Platform, NEVA educational virtual assistant, ProReach services, and Constellation platform round out the broader offering.
Differentiator
Problem solved
Functional benefit
Brands
- Signatera: Personalized, tumor-informed molecular residual disease (MRD) assay for cancer recurrence monitoring and treatment guidance.
- Latitude
- Altera
- Empower
- Prospera
- Renasight
- Horizon
- Panorama
- Vistara
- Anora
- Vasistera
- Fetal Focus
- Zenith
- Constellation
- NateraConnect
- NateraCore Services
- NEVA for Empower
- Spectrum
Products and services
- Signatera
- Signatera Genome
- Latitude
- Altera
- Empower
- Prospera
- Renasight
- RenasightIQ
- Horizon
- Panorama
- Vistara
- Fetal Focus
- Vasistera
- Anora
- Zenith
- CLARITY MRD Assay
- Spectrum
Quantifiable outcome
- Signatera-positivity associated with HR 8.15 in adjuvant setting and HR 18.30 in surveillance across a meta-analysis of 18 studies, 3,000+ patients, 15 tumor types (ASCO 2026)
- +8 more outcomes
Companies that use Natera
Customer profileSegments5 records
Ideal customer profiles5 records
Natera technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
AI capability9 records
Feature8 records
Natera partnerships and signals
Strategic signalPartnerships
Ten partnerships are on record, tiered core and minor.
- SRL Inc.coreSRL Inc. is Natera's exclusive business partner to commercialize Signatera in Japan following PMDA approval in colorectal cancer. Commercial launch planned by year-end 2026 with SRL supporting commercialization and access expansion across the country.
- Pirche AGcorePirche AG and Natera announced a strategic collaboration to advance transplant medicine by combining Pirche's TxPredictor pre-transplant immunological risk-stratification platform with Natera's Prospera dd-cfDNA post-transplant monitoring test. Joint launch planned at the 2026 American Transplant Congress.
- CytoDyn Inc.coreNatera and CytoDyn announced a strategic collaboration to evaluate circulating tumor DNA (ctDNA) dynamics using Signatera on samples from CytoDyn's CLOVER Phase 2 study in metastatic colorectal cancer, plus access to Natera's proprietary oncology database (2M+ plasma timepoints) for molecular response analysis in leronlimab development.
- Diakonos Oncology Corp.coreNatera and Diakonos Oncology Corp. announced a collaboration for Signatera to assess molecular response in patients with refractory melanoma enrolled in Diakonos' DOC-RM Phase I/II trial evaluating DOC1021 (dubodencel), a personalized dendritic cell therapy with FDA Fast Track designation. Natera will perform serial ctDNA monitoring at multiple timepoints.
- NVIDIAcoreNatera partners with NVIDIA to enhance its AI models for cell-free DNA-based early cancer detection; Natera is cited as a leading example of a biotech that applies AI to cfDNA technology.
- Genentech (Tecentriq)coreFDA approval of Genentech's Tecentriq / Tecentriq Hybreza as adjuvant treatment for muscle-invasive bladder cancer patients identified as ctDNA-MRD positive by Natera's Signatera CDx, supported by the IMvigor011 Phase III study (36% reduction in recurrence or death; 41% reduction in overall death).
- Purespring Therapeutics (with Bristol Renal / Genescape / Travere Therapeutics)minorNatera collaborated on Purespring Therapeutics' publication in Kidney International Reports identifying NPHS2 variants as a significant under-recognised cause of adult-onset FSGS, informing development strategy for Purespring's PS-001 candidate treatment.
- BGI Genomics Co., Ltd.coreStrategic collaboration with BGI Genomics for developing NGS-based genetic testing assays, cited as a key partnership in stock analyses of Natera.
- Allogene TherapeuticscoreNatera's CLARITY MRD assay is being used to identify MRD-positive patients in Allogene Therapeutics' registrational ALPHA3 trial of cema-cel in first-line large B-cell lymphoma. Interim futility analysis showed 58.3% MRD clearance in the cema-cel arm vs. 16.7% observation.
- MyOmecoreExclusive partnership with MyOme to develop Natera's Zenith whole-genome sequencing rare-disease platform, designed to shorten the 4-7 year diagnostic odyssey for rare disease patients.
Scale indicators16 records
Recent moves7 records
Expansion highlights6 records
Natera competitors and assessment
Company assessmentDirect peers
- Guardant Health: Direct competitor in blood-based cancer diagnostics. Guardant360 (liquid biopsy CGP) and Guardant Reveal (tumor-naive MRD assay) overlap with Natera's Altera and Signatera franchises, targeting the same oncologists and biopharma partners.
- Exact Sciences: Oncology diagnostics competitor with Cologuard (CRC screening), the Thrive/Earli detection platform, and Oncodetect MRD. Competes for the same clinician wallet and biopharma companion-diagnostic relationships as Natera's oncology franchise.
- Adaptive Biotechnologies: Competitor in MRD with the FDA-approved clonoSEQ assay for hematologic malignancies (ALL, MM, CLL). Also offers T-cell receptor immunodiagnostics. Direct overlap with Natera's hematology MRD work via CLARITY (acquired with Foresight).
- Caris Life Sciences: Competitor in molecular profiling (MI Profile, MI Cancer Seek) and AI-driven multi-omics. Targets oncology clinicians and biopharma with similar use cases to Natera's Altera and CLARITY franchises.
- Myriad Genetics: Genetic testing competitor with overlapping prenatal/women's health (Foresight, Prequel), hereditary cancer, and oncology products. Direct overlap with Natera's Panorama, Horizon, Empower, and Vistara franchises.
- CareDx: Direct competitor in transplant diagnostics with AlloSure (dd-cfDNA) for kidney and heart transplant monitoring. Competes head-to-head with Natera's Prospera in the same transplant centers and is also an active IP adversary.
Broad incumbents
- Foundation Medicine: Roche subsidiary and broad incumbent in comprehensive genomic profiling (FoundationOne CDx, FoundationOne Liquid CDx). Competes with Natera's Altera and Signatera within oncology workflows and has deep pharma/biopharma penetration.
- NeoGenomics: Oncology-focused clinical laboratory services company offering CGP, MRD (RaDaR), and hematology testing. Competes with Natera in oncology hospital and biopharma channels; broader menu but less MRD-specific depth.
Emerging players
- Tempus AI: AI-enabled precision medicine company offering genomic profiling, real-world data, and biopharma services. Adjacent competitor to Natera's biopharma services business, with overlapping pharma clients but a different technical foundation (DNA/RNA + imaging vs. cfDNA).
- Veracyte: Genomic diagnostics company focused on urology (Decipher Prostate), thyroid, and lung. Increasingly competing with Natera's oncology CGP and emerging MRD urology applications, with similar sales motion into specialist clinicians.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Natera social profiles
Digital presenceNatera compliance and trust
Trust signalCompliance6 records
Natera financial estimates
Financial estimateRevenue estimate
Valuation estimate
Natera leadership team
Management profileNumber of profiles
Profiles21 records
Natera subsidiaries and ownership
Company hierarchySubsidiaries1 record
Natera funding detail
Funding detailFunding overview
Funding rounds14 records
Investors13 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Natera M&A and investment
M&A and investmentM&A1 record
Investments2 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Natera
What does Natera do?
Natera runs cell-free DNA (cfDNA) diagnostic tests in its ISO 13485/CAP/CLIA-certified laboratories, sold to clinicians, health systems, and biopharma customers. Its core franchise is Signatera, a personalized tumor-informed molecular residual disease (MRD) assay for cancer recurrence monitoring, complemented by Prospera dd-cfDNA transplant rejection tests (kidney, heart, lung), Panorama NIPT and women's health reproductive tests, Renasight kidney gene panels, and the Zenith whole-genome rare-disease platform.
Is Natera a public or private company?
Natera is a public company. It is classified as public and is currently operating.
When was Natera founded?
Natera was founded in 2004. It employs 5,001 to 10,000 people.
Where is Natera based?
Natera is headquartered in San Carlos, United States, in the North America region.
How does Natera make money?
Four revenue lines are on record. Clinical diagnostic testing services are the primary driver. The others are biopharma services and partnerships, MRD patent licensing royalties and renasight / RenasightIQ pharma research and clinical-trial services.
Who are Natera's main competitors?
Direct peers on record are Guardant Health, Exact Sciences, Adaptive Biotechnologies, Caris Life Sciences, Myriad Genetics and CareDx. Broad incumbents are Foundation Medicine and NeoGenomics. Emerging players are Tempus AI and Veracyte.
Does Natera have an API?
No public API is recorded for Natera.